EcoDrugPlus

Dopamine Receptor D2

Ensembl ID : ENSOCUG00000011657
Gene Symbol: DRD2
3 Cross references
219 Possible Orthologues:

Dopamine Receptor D3

Ensembl ID : ENSOCUG00000002605
Gene Symbol: DRD3
2 Cross references
206 Possible Orthologues:

Dopamine Receptor D5

Ensembl ID : ENSOCUG00000026757
Gene Symbol: DRD5
2 Cross references
186 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSOCUG00000013534
Gene Symbol: ENPP2
2 Cross references
227 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSOCUG00000013221
Gene Symbol: EGLN1
3 Cross references
227 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 2

Ensembl ID : ENSOCUG00000023222
Gene Symbol: EGLN2
3 Cross references
190 Possible Orthologues:

Endothelial Pas Domain Protein 1

Ensembl ID : ENSOCUG00000014904
Gene Symbol: EPAS1
2 Cross references
222 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSOCUG00000011960
Gene Symbol: ECE1
2 Cross references
230 Possible Orthologues:

Endothelin Receptor Type A

Ensembl ID : ENSOCUG00000001250
Gene Symbol: EDNRA
3 Cross references
265 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSOCUG00000017780
Gene Symbol: EDNRB
3 Cross references
264 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSOCUG00000001676
Gene Symbol: EZH2
2 Cross references
222 Possible Orthologues:

Epidermal Growth Factor Receptor

Ensembl ID : ENSOCUG00000010481
Gene Symbol: EGFR
2 Cross references
285 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).